Stryker Corp (SYK)
NYSE:SYK
Want to see SYK full AI Analyst Report?
SYK Stock Chart & Stats
$343.32
$6.61(1.86%)
At close: 4:00 PM EST
$343.32
$6.61(1.86%)
Day’s Range― - ―
52-Week Range$281.00 - $404.87
Previous CloseN/A
Volume378.36K
Average Volume (3M)2.85M
Market Cap
$112.44B
Enterprise Value$128.31B
Total Cash (Recent Filing)$2.96B
Total Debt (Recent Filing)$14.22B
Price to Earnings (P/E)33.7
Beta0.60
Next Earnings
Jul 30, 2026EPS Estimate
3.49Next Dividend Ex-DateN/A
Dividend Yield0.95%
Share Statistics
EPS (TTM)8.73
Shares Outstanding383,360,750
10 Day Avg. Volume3,350,367
30 Day Avg. Volume2,854,171
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)5.99
Price to Sales (P/S)5.35
P/FCF Ratio31.36
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue5.08
Enterprise Value/Gross Profit7.97
Enterprise Value/Ebitda22.18
Forecast
1Y Price Target
$391.67Price Target Upside14.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
EPS Forecast (FY)14.98
Revenue Forecast (FY)$27.27B
Bulls Say, Bears Say
Bulls Say
Scale & Margin DurabilityStryker’s material revenue scale and persistently high gross margins provide structural advantage: larger R&D and commercial investments, broader cross-selling across ortho/MedSurg/Neuro, and greater pricing leverage versus smaller peers, supporting durable profitability and reinvestment capacity over time.
Strong Free Cash Flow GenerationConsistent high operating cash flow and sizable free cash flow give Stryker durable financial flexibility to fund M&A, capex for installed-base growth, service debt and return capital. Reliable cash conversion also underpins capacity to invest in long-cycle initiatives and product development.
Robotics & Installed‑base MomentumAccelerating Mako installations and utilization create an expanding installed base that drives recurring disposables, software and services revenue. Robotic leadership and new launches (Mako 4, RPS handheld) strengthen clinical preference and long-term platform stickiness across orthopedic procedures.
Bears Say
Large Absolute Debt LoadA substantial absolute debt position increases sensitivity to higher interest rates and refinancing cycles, limiting flexibility for large buybacks or bolt‑on M&A without adding leverage. Even with improving ratios, the absolute burden raises long‑term funding and covenant risks versus lower‑leverage peers.
Margin Compression / Profitability PressureErosion from tariffs, lost manufacturing absorption and rising other expense has compressed margins. Sustained margin pressure would reduce cash flow elasticity, constrain R&D/capex tradeoffs and limit the company’s ability to absorb future cost shocks or fund strategic investments without raising prices or cutting programs.
Cybersecurity & Operational RiskA major cyber event that disrupted order processing and manufacturing highlights persistent operational and reputational risk. Remediation and hardening require ongoing investment and create potential regulatory, customer trust and supply‑chain vulnerabilities that can depress organic growth and margins long after the incident.
Stryker News
SYK FAQ
What was Stryker Corp’s price range in the past 12 months?
Stryker Corp lowest stock price was $281.00 and its highest was $404.87 in the past 12 months.
What is Stryker Corp’s market cap?
Stryker Corp’s market cap is $112.44B.
When is Stryker Corp’s upcoming earnings report date?
Stryker Corp’s upcoming earnings report date is Jul 30, 2026 which is in 56 days.
How were Stryker Corp’s earnings last quarter?
Stryker Corp released its earnings results on Apr 30, 2026. The company reported $2.6 earnings per share for the quarter, missing the consensus estimate of $2.981 by -$0.381.
Is Stryker Corp overvalued?
According to Wall Street analysts Stryker Corp’s price is currently Undervalued.
Does Stryker Corp pay dividends?
Stryker Corp pays a Quarterly dividend of $0.84 which represents an annual dividend yield of 0.95%. See more information on Stryker Corp dividends here
What is Stryker Corp’s EPS estimate?
Stryker Corp’s EPS estimate is 3.49.
How many shares outstanding does Stryker Corp have?
Stryker Corp has 383,360,750 shares outstanding.
What happened to Stryker Corp’s price movement after its last earnings report?
Stryker Corp reported an EPS of $2.6 in its last earnings report, missing expectations of $2.981. Following the earnings report the stock price went down -6.474%.
Which hedge fund is a major shareholder of Stryker Corp?
Currently, no hedge funds are holding shares in SYK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stryker Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$391.67 (14.08% Upside)
$391.67 (14.08% Upside)
Blogger Sentiment
Bullish
SYK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $99.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 9.9%
Last 30 Days ▲ 9.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.24%
12-Months-Change
Fundamentals
Return on Equity
15.22%
Trailing 12-Months
Asset Growth
0.62%
Trailing 12-Months
Company Description
Stryker Corp
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
SYK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call mixed a significant near-term operational setback—the late-quarter cyber incident that materially distorted Q1 results, pressured margins and reduced EPS—with several strong positives: rapid operational recovery, record Mako installations and robust robotic momentum, continued healthy underlying demand, strategic reorganization (Ortho Tech), active M&A (AVS) and maintained full-year guidance (organic sales growth 8.0%–9.5%, adjusted EPS $14.90–$15.10). Management expects most lost Q1 sales to be realized through the rest of the year, with catch-up skewed to the back half, and emphasized customer/employee support and successful recovery efforts.View all SYK earnings summariesSYK Net sales Breakdown
62.30% MedSurg and Neurotechnology
37.70% Orthopaedics and Spine
SYK Stock 12 Month Forecast
Average Price Target
$391.67
▲(14.08% Upside)
Technical Analysis
Abbott Laboratories
―
Boston Scientific
―
Edwards Lifesciences
―
Medtronic
―
Zimmer Biomet Holdings
―
Ownership Overview
4.00% Insiders
19.52% Mutual Funds
20.72% Other Institutional Investors
36.16% Public Companies and Individual Investors